Atyr Pharma Inc. (NASDAQ:LIFE)’s share price fell 2.7% during mid-day trading on Monday . The stock traded as low as $2.82 and last traded at $2.90, with a volume of 54,261 shares trading hands. The stock had previously closed at $2.98.

Several brokerages have recently issued reports on LIFE. Citigroup Inc. boosted their price target on shares of Atyr Pharma from $3.00 to $4.00 and gave the company a “neutral” rating in a report on Tuesday, August 16th. Zacks Investment Research raised shares of Atyr Pharma from a “hold” rating to a “buy” rating and set a $4.00 target price for the company in a research note on Tuesday, August 16th. JPMorgan Chase & Co. reduced their target price on shares of Atyr Pharma from $15.00 to $10.00 and set an “overweight” rating for the company in a research note on Thursday, August 11th. Finally, BMO Capital Markets reaffirmed a “hold” rating on shares of Atyr Pharma in a research note on Thursday, May 12th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Atyr Pharma has a consensus rating of “Hold” and an average target price of $6.00.

The firm’s market cap is $68.78 million. The company has a 50 day moving average of $3.08 and a 200 day moving average of $3.63.

Atyr Pharma (NASDAQ:LIFE) last released its quarterly earnings results on Wednesday, August 10th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.71) by $0.06. Equities analysts anticipate that Atyr Pharma Inc. will post ($2.56) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Atyr Pharma stock. RS Investment Management Co. LLC raised its stake in shares of Atyr Pharma Inc. (NASDAQ:LIFE) by 11.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,206,249 shares of the company’s stock after buying an additional 124,000 shares during the period. RS Investment Management Co. LLC owned 5.10% of Atyr Pharma worth $11,857,000 as of its most recent SEC filing.

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.